INVIVYD INC. - COMMON STOCK

1,4000

13-февраля-25 14:51:38

15 мин. задержка

Акции

-0,1200

-7,89%

Сегодняшний диапазон

1,3000 - 1,4699

ISIN

N/A

Источник

NASDAQ

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

10 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

05 фев 2025 09:30:18 Источник Nasdaq GlobeNewswire
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

03 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

03 фев 2025 06:55:00 Источник Nasdaq GlobeNewswire
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

27 янв 2025 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

10 янв 2025 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 ноя 2024 07:05:00 Источник Nasdaq GlobeNewswire
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

14 ноя 2024 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

12 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

06 ноя 2024 08:01:00 Источник Nasdaq GlobeNewswire
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

06 ноя 2024 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

29 окт 2024 07:03:00 Источник Nasdaq GlobeNewswire
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

29 окт 2024 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

16 окт 2024 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

01 окт 2024 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

23 сен 2024 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

12 сен 2024 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences

05 сен 2024 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

04 сен 2024 07:01:00 Источник Nasdaq GlobeNewswire
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

03 сен 2024 07:01:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.